Podocalyxin is a CD34-related cell surface molecule with anti-adhesive qualities. We probed a tissue microarray (n ‫؍‬ 272) linked to long-term outcome data and found that podocalyxin was highly overexpressed in a distinct subset of invasive breast carcinomas (n ‫؍‬ 15; 6%). Univariate disease-specific (P < 0.01) and multivariate regression (P < 0.0005) analyses indicated that this overexpression is an independent indicator of poor outcome. Forced podocalyxin expression perturbed cell junctions between MCF-7 breast carcinoma cells, and it caused cell shedding from confluent monolayers. Therefore, podocalyxin overexpression is a novel predictor of breast cancer progression that may contribute to the process by perturbing tumor cell adhesion.
Introduction
The expression of specific cell junction proteins is often suppressed in breast tumors and the resulting perturbation of cell-cell interactions is thought to facilitate the emergence of the metastatic phenotype (1) . As the degree and the specificity of junctional disruption varies widely with stage, grade, and tumor subtype, we reasoned that an up-regulation of anti-adhesive molecules might also be involved in breast cancer progression. Podocalyxin, which is normally expressed on hematopoietic progenitors, vascular endothelia, and kidney podocytes is a heavily sialated and sulfated member of the CD34 family of integral membrane proteins that is one such candidate anti-adhesin (2-4). Podocalyxin's anti-adhesive characteristics are evident when it is overexpressed in kidney epithelial cells where it subtly perturbs cell junction protein localization and decreases tight junction-dependent transepithelial resistance (5) . We found the same to be the case when podocalyxin was overexpressed in MCF-7 breast carcinoma cells. Using a tissue microrray (TMA) linked to long-term outcome data characterized previously (6), we assessed changes in podocalyxin expression in 272 invasive human breast carcinomas. The results indicate that podocalyxin overexpression is tightly correlated with poor outcome in a distinct subset of tumors. Taken together, the data indicate that podocalyxin overexpression may have both prognostic and functional significance in breast cancer progression.
Materials and Methods
TMA Construction. Formalin-fixed, paraffin-embedded primary invasive breast cancer tissue blocks (outcome-linked archival cases from 1974 -1995) graded according to the Nottingham method were used to construct a TMA as described previously (7) with institutional review board approval (Vancouver General Hospital, Vancouver, Canada). This TMA contains many tumors in terms of stage, grade, and nodal status. In addition, estrogen receptor, p53, and Her-2/neu status was determined previously (6) .
TMA Immunohistochemistry, Scoring, and Analysis. Deparaffinized, citrate buffer-treated normal tissue and TMA sections were blocked with 3% hydrogen peroxide and incubated with mouse monoclonal antibodies against human podocalyxin (clone "3D3"; 1:80 dilution; Ref. 8) and CD34 (clone "8G12"; BD Biosciences, San Diego, CA) followed by detection with the Envision system (Dako, Carpinteria, CA) and hematoxylin counterstaining. Podocalyxin levels were scored by staining intensity, and the proportion of cells were stained (see Results below for description of groupings) without knowledge of patient outcome. Scores were then processed using the TMADeconvoluter 1.06, Cluster and TreeView programs (9) . Differences among podocalyxin groupings in terms of disease-free survival were assessed by univariate Kaplan-Meier analysis (log-rank test). Multivariate analysis of disease-specific survival was performed using the multi-step Cox regression proportional hazard model (confidence interval, 99%).
Cell Culture, Transfection, and Junctional Analysis. T47D, MCF-7, and MDA-231 human breast carcinoma cell lines were routinely maintained in DMEM/F12 medium supplemented with 5% fetal bovine serum and insulin (5 g/ml). Endogenous podocalyxin levels were determined by Western blotting of whole cell lysates from subconfluent cultures using the 3D3 antibody.
MCF-7 cells, which expressed low levels of endogenous human podocalyxin (see Fig. 3A ), were transfected with a control pIRES-enhanced green fluorescent protein (EGFP) expression vector (BD Biosciences) or with the same vector containing a full-length mouse podocalyxin cDNA (10) . We chose to express the mouse gene in the human cells for two reasons. First, we had a mouse-isoform-specific antibody on hand (10) , and it has not yet been established if epitope tagging can be successfully carried out without affecting podocalyxin function/localization (see below). Second, although there are differences in the extracellular domain of podocalyxin across species, these are largely restricted to the mucin domains whereas the cytoplasmic domains are Ͼ90% identical (11) . Within the mucin domains, although these molecules lack linear sequence homology, they contain a very similar frequency of serine, threonine, and proline residues which is the key prerequisite for the O-linked glycosylation that allows these molecules to block adhesion (5, 10) . Pooled, stable transfectant populations were generated under G418 (400 g/ml) selection.
EGFP and coincident podocalyxin transgene expression was confirmed by dual fluorescence excitation for EGFP and immunofluorescence using a rat monoclonal antibody against mouse podocalyxin (1:100; Ref 10) . Ectopic podocalyxin localization was determined by Z-series confocal microscopy in Transepithelial resistance was assessed on confluent monolayers maintained on Transwell filters with a 3-m pore size (Costar) using a Millicell electrical resistance system (Millipore, Bedford, MA) according to the manufacturer's instructions. Each transfectant was assessed in duplicate cultures; variation was Ͻ10% of the mean, and the data presented are representative of two independent experiments.
Results

Podocalyxin is Highly Expressed in a Subset of Invasive Breast
Carcinomas. Podocalyxin was present on podocytes, but not tubular cells, in normal kidney sections (data not shown) confirming that the appropriate conditions were being used for the immunostaining (8) .
Podocalyxin was also present in normal breast epithelia, but its expression was limited, and its localization was spatially restricted. Specifically, podocalyxin was localized to the apical region of luminal epithelial cells ( Fig. 1A ; inset, arrowheads). As expected, it was also present on vascular endothelial cells in both normal breast and breast tumor tissue (Fig. 1, A and B, arrows) .
Sixty percent (163 of 272) of the invasive breast cancer cases on the TMA did not exhibit detectable podocalyxin in the tumor cells, and they were assigned a score of "0" (Fig. 1B) ; 23% (62 of 272), exhibited staining in Ͻ10% of the tumor cells, and were assigned a score of "1" (Fig. 1C) ; 12% (32 of 272) exhibited diffuse staining in Ͼ10% of the cells and/or intense staining in Ͻ50% of the cells and were assigned a score of "2" (Fig. 1D) . The remaining 6% (15 of 272) of the cases on the TMA exhibited intense podocalyxin staining in the majority of the tumor cells, and they were assigned a score of "3" (Fig. 1E ). There was no evidence that the intense podocalyxin staining observed in group 3 tumor cells colocalized with CD34 ( Fig. 1F and  G) . Thus, the podocalyxin staining observed on the TMA was very likely specific for this particular member of the CD34 family.
Univariate Kaplan-Meier analysis of disease-specific survival (logrank test) indicated that the high podocalyxin expression group (i.e., group 3) was associated with poor outcome (Fig. 2) . This was most clearly evident when the extremes were compared (i.e., group 0 versus group 3, P ϭ 0.007; and 1 versus 3, P ϭ 0.04). Although there was a trend in a similar direction, a statistically significant difference was no longer evident when the moderate (group 2) and high overexpressors were compared (2 versus 3, P ϭ 0.1). Comparisons between all other individual groups showed no trends or statistical significance (P ϭ 0.6 -0.8). Thus, for further analysis we pooled groups 0, 1, and 2 (i.e., low/no podocalyxin) and compared them to group 3 only (i.e., high podocalyxin).
There were statistically significant differences in both cumulative disease-free (P ϭ 0.01) and overall (P ϭ 0.025) survival rates between the pooled low/no podocalyxin and high podocalyxin groups. As a result, the high podocalyxin group had a much lower mean survival time of 9.0 Ϯ 1.8 years compared with 15 Ϯ0.5 years for the combined low/no podocalyxin pool. The mean survival time of the entire TMA population was 14.9 years.
High Podocalyxin Expression Is an Independent Marker of Poor Outcome. A comparison of clinicopathological characteristics indicated that there were no significant differences in histological subtype, tumor size, lymph node status, or Her-2/neu staining between the low/no podocalyxin pool and the high podocalyxin expressors (Table 1 ). In contrast, there were proportionally more high grade, estrogen receptor negative and abnormal p53 tumors in the high podocalyxin expression group (Table 1) .
We next performed a multi-step, Cox regression proportional hazard analysis ( Table 2) . As expected, regional lymph node involvement was an independent indicator of poor outcome (P ϭ 0.012). Strikingly, high podocalyxin expression, on its own, was also a highly significant independent predictor of poor outcome (P ϭ 0.0005). Furthermore, the increased relative risk associated with high podocalyxin expression (8.4-fold), although broad in terms of confidence interval, was as great, or greater, than either regional lymph node involvement or Her-2/neu overexpression. Thus, podocalyxin overexpression identifies a unique subpopulation of invasive breast tumors with an increased potential to undergo progression. (Fig. 3A) . T47D and MCF-7 breast carcinoma cells, which are weakly metastatic and estrogen receptor positive, contained considerably less podocalyxin than MDA-231 breast carcinoma cells, which are highly metastatic and estrogen receptor negative.
MCF-7 cells form cohesive, junction-containing monolayers, and were thus chosen for ectopic overexpression studies. Cells stably transfected with a control EGFP-expressing vector formed flat epithelial cobblestone monolayers that were indistinguishable from those observed in the parental MCF-7 line (Fig. 3B, top panel; data not shown). In contrast, cells stably transfected with the same vector encoding EGFP and a full-length mouse podocalyxin cDNA formed monolayers that contained areas where the cells bulged apically. When these podocalyxin-transfected cultures reached confluence the bulging cells delaminated from the monolayer and were shed into the medium (Fig. 3B, middle panel) . On the basis of triple-labeling for the EGFP marker, transgenic mouse podocalyxin, and nuclear DNA, it was clear that the ectopically expressed podocalyxin was appropriately targeted to the cell surface and that the cells expressing this protein were often apically displaced in the monolayer (Fig. 3B,  bottom panel) .
In this initial study, we chose to analyze cell junction protein localization in pooled transfected populations as this afforded us internal controls in which ectopic podocalyxin was expressed at levels below the limits of detection. Additionally, those cells that did express ectopic mouse podocalyxin in the pooled population did so at levels that were similar to endogenously expressed podocalyxin in mouse endothelial cells (Fig. 3C ).
As expected, the adherens junction protein E-cadherin was localized basolaterally in vector control-transfected MCF-7 cells (Fig. 3D,  top panel) . In contrast, E-cadherin was often localized around the entire cell circumference in the podocalyxin expressing transfectants.
The tight junction protein ZO-1, which was apically localized in discrete terminal bars in the control cells, was found at multiple levels in the podocalyxin transfectants (Fig. 3D, bottom panel) . In addition, transepithelial resistance, which is a functional measure of tight junction patency (5), was significantly reduced in the podocalyxin-transfected cultures (210 ohms cm 2 ) compared with the vector alonetransfected cells (497 ohms cm 2 ). Therefore, we conclude that podocalyxin was capable of perturbing cell junctions between MCF-7 cells.
Discussion
Locally invasive breast cancers, particularly those in which regional lymph node involvement has not been detected at the time of diagnosis, can have markedly different outcomes. Thus, it is extremely difficult to predict which patients with these lesions will most benefit, or not benefit, from adjuvant therapy. Large scale expression profiling has had some impact on this problem, particularly in terms of identifying those tumors that will not progress, which constitutes the majority of the diagnosed lesions of this type (12) . Despite these advances, the identification of novel independent indicators of poor outcome continues to be useful as it increases the resolving power of all prognostic strategies. Our initial study with a moderately sized (n ϭ 272) tissue array indicates that high podocalyxin overexpression is very likely such an independent prognostic indicator. However, we are currently screening a much larger TMA (n ϭ 3000) to confirm this conclusion. We are also expanding our screening efforts to include other members of the CD34 family, including endoglycan (10, 13) .
In addition to invasive breast cancers, podocalyxin is also overexpressed in high-grade ovarian carcinomas, 6 and it is dysregulated in human embryonal carcinomas (14) . The human podocalyxin gene (PODXL) has been assigned to chromosome 7q32-q33 (15) . This places PODXL between two regions, 7q21-q22 and 7q35ter, that have been identified as chromosomal gain sites by comparative genomic hybridization in ductal breast carcinoma in situ, infiltrating ductal carcinoma, and in breast tumor lines (16, 17) . Because 7q32-33 has not specifically been implicated as a frequent region of chromosomal gain, it is not surprising that we were only able to identify one PODXL amplification event, using fluorescent in situ hybridization, among the 15 overexpressors on the TMA. 7 The paucity of amplification events suggests that podocalyxin gene NOTE. Cox expression multivariate analysis of disease-specific survival. * Considered a significant independent indicator of poor outcome at P Ͻ 0.05. † Mean-fold increase in relative risk of the group compared to the entire population used to generate the tissue microarray.
‡ Upper and lower margins of relative risk using two standard deviations of variation about the mean. expression and/or protein stability are dysregulated in the group 3, high expressing tumors. Although a detailed dissection of the podocalyxin promoter has not yet been performed, the expression of the gene is altered, either directly or indirectly, by estrogen signaling during normal mammary gland development (18) . Steady-state levels and the localization of podocalyxin, both of which were altered in the high expressing tumors, might also be regulated by functionally important binding proteins. One class of binding proteins worth considering in this regard are the sodium-hydrogen exchanger regulatory factors that interact with the cytoplasmic domain of podocalyxin and link it to the actin cytoskeleton (19) . Interestingly, sodium-hydrogen exchanger regulatory factor-1 is often down-regulated in estrogen receptor-negative breast tumors (20) , and the majority of the group 3 high podocalyxin expressors on the TMA were estrogen receptor negative.
It has been proposed that the disruption of epithelial cell junctions contributes to invasive breast carcinoma progression (1). During normal kidney development, podocalyxin, which is the major glomerular anion, disrupts epithelial cell junctions between differentiating podocytes during the formation of the primary urinary filter (10) . Additionally, forced overexpression of human podocalyxin perturbs cell junctions in cultured canine MDCK cells (5) . We found that forced overexpression of podocalyxin initiated similar changes in human MCF-7 breast carcinoma cells. We are now carrying out combinatorial oncogene/podocalyxin expression experiments to definitively determine whether this anti-adhesive ability contributes to the metastatic progression in vivo. If this turns out to be the case, in addition to its prognostic significance, podocalyxin could become a new therapeutic target in the fight against breast cancer progression.
